Manchanda added that the anti-infectives treating HIV, TB and drug cessation treatments in the list doesn't have a major impact on margins ...

Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 14647.01 Crore) operating in Pharmaceutic...

The widely-used drug saw sales soar 20X during the third wave of the pandemic. It registered a 100% jump in January over the previous month...

Drugmaker Biocon is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and pr...

Sanofi India’s management has adopted cost control measures and has lowered promotional spends, which was visible in 2020. Its digital push...

A 30-year-old brand manufactured by the little-known Apex Labs, Zincovit registered sales of Rs 50 crore during October, dethroning the lar...

"We are extremely pleased with the US PTAB's ruling in favour of our partner Mylan for four device patents of Sanofi's Lantus SoloSTAR. Thi...

Firms have been asked to share details about a change in the manufacturing site for glargine from Bengaluru to a new facility in Malaysia.

Sanofi reported one of the sharpest falls in its global sales in the fourth quarter, owing to the decline in diabetes drug sales, a controv...

The once-a-week non-insulin injectable Trulicity is distinct in the duration of dosage compared to products like Novo Nordisk's Victoza or ...

However, unlike other multinational pharmaceutical companies, Sanofi India was not analysts’ favourite for quite some time.

Novo is betting big on Tresiba in the emerging markets after it failed to get an approval for the drug from the US Food and Drug Administra...

The companies give patients more than just the daily dose, helping them with counselling, diagnostic tests, freebies, diet or exercise advi...

Oral anti-diabetes segment grew 29.7% for the nine-month period ended August 2010 over the year ago period compared with 22.9% increase in ...

Sanofi-Aventis which bought companies in Brazil, Mexico, and the home-grown Shanta Biotech this year, has sent a delegation to India to fin...

New York's main contract, light sweet crude for September delivery was at $71.43 per barrel, after surging $2.13 in previous session. Brent...

Sanofi-aventis reported a 12% drop in third-quarter profit on Tuesday, citing the loss of top-selling blood thinner Plavix to generic compe...